07/18/2024
Happy to say we are seeing great results in the use of Arthramid Vet.
ConturaVet Newsletter
Advancing Equine Joint Health with New Research on Arthramid Vet at Colorado State University’s C. Wayne McIlwraith Translational Medicine Institute & Equine Orthopaedic Research Center.
Exciting Research News
Dear Veterinarians,
We are excited to share some fantastic research updates with you. Last week, the ConturaVet Equine Team had an inspiring time in Colorado. One of the highlights of our trip was touring the Colorado State University C. Wayne McIlwraith Translational Medicine Institute and Orthopaedic Research Center, where 2.5% polyacrylamide hydrogel (Arthramid Vet) will be evaluated via the equine osteochondral fragment model for osteoarthritis. During our visit, we had the privilege of meeting our research horses and engaging with the brilliant veterinary researchers who are overseeing our study. This study commenced last week!
Commitment to Research and Innovation
At ConturaVet, we are deeply committed to conducting ongoing, meaningful research. Our goal is to continually elevate the tools veterinarians use to practice the best medicine. We are excited about the promising outcomes of our latest research on improving joint health in horses. Our dedication to this mission is unwavering, and we are proud to support the veterinary community with cutting-edge solutions.
24 Years of Development: Arthramid Vet’s “2.5 iPAAG”
The Arthramid Vet formula, “2.5 iPAAG”, features 2.5% polyacrylamide and 97.5% sterile water, a product of 24 years of rigorous development and history. This innovative formula is designed to significantly improve joint health in horses and other animals including dogs and humans. Its efficacy and safety are backed by research that began in horses in 2012, following research and use in humans in 2000. Continued research in horses has been published nearly every year since 2012 making it a trusted choice for equine veterinarians seeking the best outcomes for their patients around the world.
Promising Research Outcomes
As we embark on this significant study at CSU’s Orthopaedic Research Center, we are optimistic about the potential findings and their impact on equine joint health. Our collaboration with the experts at Colorado State University promises to yield valuable insights that will further enhance the evidence base on the effectiveness of Arthramid Vet.
One Health: Arthramid Vet and Arthrosamid
The “One Health” approach underscores the interconnectedness of human and animal health. Arthramid Vet’s success in treating joint health issues in horses extends beyond equine applications. Our product is also used for dogs suffering from osteoarthritis, providing them with relief and improved mobility.
In addition, our human-use product, Arthrosamid, has shown significant promise in treating knee osteoarthritis in Europe. Three-year efficacy data from various studies in humans have been published and we eagerly await the upcoming publication of the four-year data as part of the ongoing 5 year trials.
Stay tuned for the results of the groundbreaking CSU research.
We are excited to share our progress and continue supporting you with the latest advancements in equine medicine.
Thank you for your continued trust in ConturaVet.
Michaela Arcaro
Vice President of Operations
Learn More About Arthramid Vet
